Biochemical Monitoring During Isotretinoin Treatment: Review of International Guidelines and Recent Evidence

Abstract

Isotretinoin remains the most effective systemic therapy for severe, nodulocystic, or treatment-resistant acne, achieving high rates of remission and preventing long-term scarring. Despite its efficacy, isotretinoin is associated with potential systemic adverse effects, including hepatotoxicity, dyslipidemia, and hematologic alterations, which necessitate careful biochemical monitoring. International guidelines recommend baseline evaluation and ongoing monitoring of liver function tests, lipid profiles, complete blood count, and renal function, although the frequency and intensity of follow-up vary based on patient risk factors and dosage. Recent evidence supports risk-adapted monitoring strategies, indicating that low-risk patients can be safely followed with less frequent laboratory assessments, while high-risk patients benefit from monthly or bimonthly evaluations during the initial months of treatment. Most laboratory abnormalities are mild, transient, and reversible, allowing for dose adjustments or temporary discontinuation without compromising treatment efficacy. This review synthesizes current guidelines, pharmacologic mechanisms, systemic adverse effects, and recent clinical evidence, emphasizing the importance of individualized monitoring protocols that optimize safety, efficiency, and patient adherence. The findings highlight areas for further research, including the optimal monitoring frequency for low-risk populations and the long-term clinical impact of minor biochemical changes.